AstraZeneca PLC Release: NHANES Analyses Reinforce The Need For Education To Help Increased Risk Dyslipidemic Patients Aggressively Treat Their Cholesterol

Published: Nov 20, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced the results of three analyses of data from the National Health and Nutrition Examination Survey (NHANES), all of which supported that an unmet treatment need still exists for dyslipidemia patients, particularly those at high-risk. These data were presented at the 2013 American Heart Association (AHA) Scientific Sessions in Dallas, Texas.

Help employers find you! Check out all the jobs and post your resume.

Back to news